Loading
Life sciences · Journal article
Frontiers in Medicine · October 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Osteosarcoma remains a therapeutically difficult malignancy, particularly after metastatic relapse, and immune checkpoint blockade or adoptive cell therapy has not reproduced the durable responses achieved in more immunogenic cancers. The central translational problem is not a complete absence of immune activity, but marked interpatient, intratumoral, and spatial heterogeneity in immune access, antigen presentation, myeloid suppression, stromal exclusion, and target-antigen expression. This Mini Review synthesizes recent single-cell and spatial profiling studies with tissue, circulating, and clinical biomarker evidence to define a practical framework for biomarker-guided immunotherapy. Osteosarcoma ecosystems can contain lymphoid-excluded, myeloid-dominant, angiogenic-hypoxic, checkpoint-rich, and antigen-high states that may coexist within the same patient. Consequently, programmed death-ligand 1 (PD-L1) alone is unlikely to function as a reliable treatment-selection marker. A composite assessment integrating human leukocyte antigen (HLA) class I and antigen-processing competence, CD8/regulatory T-cell topology, macrophage and myeloid-derived suppressor cell programs, vascular and extracellular-matrix barriers, and quantitative surface-antigen density is more biologically defensible. Dynamic measurements, including circulating tumor DNA, soluble B7-H3, exosomal immune signals, and serial imaging, may complement tissue profiling but remain investigational. Clinical experience with checkpoint inhibitors, antiangiogenic combinations, mifamurtide, HER2-directed approaches, and emerging B7-H3-, GD2-, ALPL-1-, CD166-, IL-11Ralpha-, and NKG2D-based cellular therapies underscores the need to match mechanism to phenotype. Prospective studies should therefore use standardized, spatially resolved, and longitudinal biomarker panels to enrich trials, distinguish prognostic from predictive effects, and adapt therapy when immune exclusion or antigen escape emerges.